Related Experiment Video
Updated: May 9, 2026
11:08
A Facile Protocol to Generate Site-Specifically Acetylated Proteins in Escherichia Coli
Published on: December 9, 2017
AEG-1/MTDH/LYRIC: clinical significance
Devanand Sarkar1, Paul B Fisher
1Department of Human and Molecular Genetics, School of Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA. dsarkar@vcu.edu
Advances in Cancer Research
|July 30, 2013
Summary
AEG-1 (also known as MTDH/LYRIC) is a key regulator of cancer hallmarks like proliferation and metastasis. Its expression is a biomarker for aggressive cancers, but its precise role in prognosis requires further investigation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The AEG-1/MTDH/LYRIC protein plays a critical role in cancer progression, influencing hallmarks such as proliferation, invasion, angiogenesis, metastasis, and chemoresistance.
- Clinicopathologic studies indicate AEG-1/MTDH/LYRIC is an independent biomarker for aggressive metastatic cancers with poor prognosis.
- AEG-1/MTDH/LYRIC expression and serum antibody titers predict chemotherapy response and advanced disease stages.
Purpose of the Study:
- To comprehensively analyze the existing literature on the clinical significance of AEG-1/MTDH/LYRIC in cancer.
- To highlight consistent findings and conflicting reports regarding AEG-1/MTDH/LYRIC's role in cancer prognosis.
- To investigate the impact of AEG-1/MTDH/LYRIC protein localization (nuclear vs. cytoplasmic) on predicting disease course.
Main Methods:
- Review and analysis of published studies on AEG-1/MTDH/LYRIC.
- Examination of 'gain-of-function' and 'loss-of-function' data in human cancer cells.
- Analysis of findings from transgenic mouse models.
- Correlation of AEG-1/MTDH/LYRIC expression with clinicopathologic data across various cancers.
Main Results:
- AEG-1/MTDH/LYRIC is established as a seminal regulator of key cancer hallmarks.
- AEG-1/MTDH/LYRIC expression serves as a biomarker for aggressive metastatic disease and predicts chemotherapy response.
- Inconsistent findings exist regarding the prognostic value of nuclear versus cytoplasmic AEG-1/MTDH/LYRIC localization.
Conclusions:
- AEG-1/MTDH/LYRIC is a significant factor in cancer progression and a potential biomarker.
- Further research is needed to resolve discrepancies in the prognostic utility of AEG-1/MTDH/LYRIC localization.
- Understanding AEG-1/MTDH/LYRIC's role is crucial for developing targeted cancer therapies.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...